Eisai Japan’s CEO Naito: 2014 Price Revisions Are Harsh On Brands
This article was originally published in PharmAsia News
Executive Summary
With the guidance towards generic drug use strong at Japan’s Diagnostic Procedure Combination hospitals, the situation under the new 2014 medical fee system for branded pharmaceuticals will get even harsher, Eisai CEO Haruo Naito said at a Tokyo press conference.